ProQR Therapeutics Analyst Ratings
ProQR Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest ProQR Therapeutics (PRQR) rating was a reiterated with a price target of $0.00 to $2.00. The current price ProQR Therapeutics (PRQR) is trading at is $1.43, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/04/2023 | 39.86% | Chardan Capital | → $2 | Reiterates | Neutral → Neutral |
| 05/17/2023 | 214.69% | Cantor Fitzgerald | $5 → $4.5 | Maintains | Overweight |
| 05/17/2023 | 319.58% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 05/17/2023 | 249.65% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 03/30/2023 | 319.58% | JMP Securities | → $6 | Reiterates | → Market Outperform |
| 03/30/2023 | 249.65% | HC Wainwright & Co. | $1.5 → $5 | Maintains | Buy |
| 12/23/2022 | 249.65% | Raymond James | $2 → $5 | Maintains | Outperform |
| 12/22/2022 | 249.65% | Cantor Fitzgerald | $0.8 → $5 | Upgrades | Neutral → Overweight |
| 08/15/2022 | 4.9% | HC Wainwright & Co. | $2 → $1.5 | Maintains | Buy |
| 08/12/2022 | — | Chardan Capital | Downgrades | Buy → Neutral | |
| 08/12/2022 | 39.86% | Raymond James | → $2 | Upgrades | Market Perform → Outperform |
| 05/09/2022 | 39.86% | HC Wainwright & Co. | $4 → $2 | Maintains | Buy |
| 05/06/2022 | 39.86% | Chardan Capital | $2.5 → $2 | Maintains | Buy |
| 04/14/2022 | 74.83% | Chardan Capital | $8 → $2.5 | Maintains | Buy |
| 04/14/2022 | 249.65% | JMP Securities | $8 → $5 | Maintains | Market Outperform |
| 02/14/2022 | 459.44% | Chardan Capital | $18 → $8 | Maintains | Buy |
| 02/14/2022 | 459.44% | JMP Securities | $29 → $8 | Maintains | Market Outperform |
| 02/14/2022 | 179.72% | HC Wainwright & Co. | $20 → $4 | Maintains | Buy |
| 02/14/2022 | — | Raymond James | Downgrades | Strong Buy → Market Perform | |
| 02/01/2022 | 1228.67% | Raymond James | → $19 | Initiates Coverage On | → Strong Buy |
| 08/09/2021 | 1158.74% | Chardan Capital | $20 → $18 | Maintains | Buy |
| 05/03/2021 | 1298.6% | Stifel | → $20 | Initiates Coverage On | → Buy |
| 08/11/2020 | 1298.6% | Chardan Capital | $25 → $20 | Maintains | Buy |
| 11/19/2019 | 2207.69% | Citigroup | $40 → $33 | Maintains | Buy |
| 11/14/2018 | 2697.2% | Cantor Fitzgerald | → $40 | Initiates Coverage On | → Overweight |
| 09/19/2018 | 2347.55% | Evercore ISI Group | → $35 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/04/2023 | 39.86% | 查丹资本 | → 2 美元 | 重申 | 中性 → 中性 |
| 05/17/2023 | 214.69% | 坎托·菲茨杰拉德 | 5 美元 → 4.5 美元 | 维护 | 超重 |
| 05/17/2023 | 319.58% | JMP 证券 | → 6 美元 | 重申 | 市场跑赢大盘 → 市场跑赢大盘 |
| 05/17/2023 | 249.65% | HC Wainwright & Co. | → 5 美元 | 重申 | 购买 → 购买 |
| 03/30/2023 | 319.58% | JMP 证券 | → 6 美元 | 重申 | → 市场跑赢大盘 |
| 03/30/2023 | 249.65% | HC Wainwright & Co. | 1.5 美元 → 5 美元 | 维护 | 购买 |
| 12/23/2022 | 249.65% | 雷蒙德·詹姆 | 2 美元 → 5 美元 | 维护 | 跑赢大盘 |
| 2022 年 12 月 22 日 | 249.65% | 坎托·菲茨杰拉德 | 0.8 美元 → 5 美元 | 升级 | 中性 → 超重 |
| 08/15/2022 | 4.9% | HC Wainwright & Co. | $2 → 1.5 美元 | 维护 | 购买 |
| 2022 年 12 月 8 日 | — | 查丹资本 | 降级 | 买入 → 中性 | |
| 2022 年 12 月 8 日 | 39.86% | 雷蒙德·詹姆 | → 2 美元 | 升级 | 市场表现 → 跑赢大盘 |
| 05/09/2022 | 39.86% | HC Wainwright & Co. | 4 美元 → 2 美元 | 维护 | 购买 |
| 2022 年 6 月 5 日 | 39.86% | 查丹资本 | 2.5 美元 → 2 美元 | 维护 | 购买 |
| 2022 年 4 月 14 日 | 74.83% | 查丹资本 | 8 美元 → 2.5 美元 | 维护 | 购买 |
| 2022 年 4 月 14 日 | 249.65% | JMP 证券 | 8 美元 → 5 美元 | 维护 | 市场表现跑赢大盘 |
| 02/14/2022 | 459.44% | 查丹资本 | 18 美元 → 8 美元 | 维护 | 购买 |
| 02/14/2022 | 459.44% | JMP 证券 | 29 美元 → 8 美元 | 维护 | 市场表现跑赢大盘 |
| 02/14/2022 | 179.72% | HC Wainwright & Co. | 20 美元 → 4 美元 | 维护 | 购买 |
| 02/14/2022 | — | 雷蒙德·詹姆 | 降级 | 强势买入 → 市场表现 | |
| 2022 年 1 月 2 日 | 1228.67% | 雷蒙德·詹姆 | → 19 美元 | 启动覆盖开启 | → 强势买入 |
| 2021 年 9 月 8 日 | 1158.74% | 查丹资本 | 20 美元 → 18 美元 | 维护 | 购买 |
| 05/03/2021 | 1298.6% | Stifel | → 20 美元 | 启动覆盖开启 | → 购买 |
| 08/11/2020 | 1298.6% | 查丹资本 | 25 美元 → 20 美元 | 维护 | 购买 |
| 11/19/2019 | 2207.69% | 花旗集团 | 40 美元 → 33 美元 | 维护 | 购买 |
| 11/14/2018 | 2697.2% | 坎托·菲茨杰拉德 | → 40 美元 | 启动覆盖开启 | → 超重 |
| 09/19/2018 | 2347.55% | Evercore ISI 集团 | → 35 美元 | 启动覆盖开启 | → 跑赢大盘 |
What is the target price for ProQR Therapeutics (PRQR)?
ProQR Therapeutics (PRQR) 的目标价格是多少？
The latest price target for ProQR Therapeutics (NASDAQ: PRQR) was reported by Chardan Capital on August 4, 2023. The analyst firm set a price target for $2.00 expecting PRQR to rise to within 12 months (a possible 39.86% upside). 11 analyst firms have reported ratings in the last year.
Chardan Capital于2023年8月4日公布了ProQR Therapeutics（纳斯达克股票代码：PRQR）的最新目标股价。这家分析公司将目标股价定为2.00美元，预计PRQR将在12个月内升至12个月内（可能上涨39.86％）。去年有11家分析公司公布了评级。
What is the most recent analyst rating for ProQR Therapeutics (PRQR)?
分析师对proQR Therapeutics（PRQR）的最新评级是多少？
The latest analyst rating for ProQR Therapeutics (NASDAQ: PRQR) was provided by Chardan Capital, and ProQR Therapeutics reiterated their neutral rating.
ProQR Therapeutics（纳斯达克股票代码：PRQR）的最新分析师评级由Chardan Capital提供，ProQR Therapeutics重申了他们的中性评级。
When is the next analyst rating going to be posted or updated for ProQR Therapeutics (PRQR)?
ProQR Therapeutics（PRQR）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProQR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProQR Therapeutics was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与ProQR Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。ProQR Therapeutics的最新评级是在2023年8月4日提交的，因此你应该预计下一个评级将在2024年8月4日左右公布。
Is the Analyst Rating ProQR Therapeutics (PRQR) correct?
分析师对 proQR Therapeutics (PRQR) 的评级正确吗？
While ratings are subjective and will change, the latest ProQR Therapeutics (PRQR) rating was a reiterated with a price target of $0.00 to $2.00. The current price ProQR Therapeutics (PRQR) is trading at is $1.43, which is within the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的ProQR Therapeutics（PRQR）评级得到了重申，目标股价为0.00美元至2.00美元。ProQR Therapeutics（PRQR）目前的交易价格为1.43美元，在分析师的预测区间内。
